Blue Cross Blue Shield of Mississippi
site map

About Us   Careers    Site Map

  • Be Healthy
  • I'm a Member
  • I'm a Provider
  • I'm an Employer
  • Find Coverage

I'm a provider

You will be redirected to myBlue. Would you like to continue?

please waitPlease wait while you are redirected.

myBlue login
 Username:
 Password:
  • Forgot Password »
  • More Information »

be RxSmart

Medical & Coding Policies

Provider Network Application

Out-of-State & Non-Network

Contact Us

Provider Links

Healthy You! Provider Information »

E-solutions & Online Tools »

Provider Forms »

Articles & Updates »

National Provider Identifier »

Good Health Club for Kids »

Medical Policy Search
Printer Friendly Version Kalydeco® (Ivacaftor)

Kalydeco® (Ivacaftor)

 

DESCRIPTION

Kalydeco is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Kalydeco facilitates increased chloride transport by potentiating the gating of the G551D-CFTR protein. Kalydeco is the first available treatment for cystic fibrosis (CF) that targets the defective CFTR protein, which is the underlying cause of CF.

FDA APPROVED INDICATIONS 
Kalydeco® is FDA approved for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the CFTR gene.

IDENTIFICATION
Generic Name: Ivacaftor
Brand Name: Kalydeco®

 

POLICY

Prior authorization is required.

Kalydeco® is considered medically necessary for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the CFTR gene detected by an FDA-cleared CF mutation test. A maximum of 60 tablets per month will be approved.

After six months of therapy, documentation of improvement in FEV1, symptoms, and stabilization of disease is required for continued treatment.

 

POLICY EXCEPTIONS

None

 

POLICY GUIDELINES

Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary.

The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.

 

POLICY HISTORY

07/26/2012: New policy added.

 

SOURCE(S)

Kalydeco® Prescribing Information

 

CODE REFERENCE

This is not intended to be a comprehensive list of codes. Some covered procedure codes have multiple descriptions.

The code(s) listed below are ONLY covered if the procedure is performed according to the "Policy" section of this document.

Covered Codes

Code Number

Description

CPT-4

 

ICD-9 Procedure

 

 

ICD-9 Diagnosis

V83.81   

Cystic fibrosis gene carrier 

HCPCS

 

 

 

Top




Copyright © 2007-2013, Blue Cross & Blue Shield of Mississippi, A Mutual Insurance Company. All Rights Reserved.
An independent licensee of the Blue Cross and Blue Shield Association.

About Us  ·   Careers   ·   Terms of Use  ·   Privacy Practices  ·   Accreditation  ·   Site Map